Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients with Prostate Cancer

Eligibility Criteria

Inclusion Criteria:

* Have a diagnosis of prostate cancer and be scheduled to receive radiotherapy with concurrent androgen deprivation therapy, and presence of fatigue with severity of 1/10, on a 0-10 scale for at least 2 weeks
* Patient not regularly engaging in moderate aerobic exercise for >90 minutes/week and/or vigorous aerobic exercise for >30 minutes/week, and/ or strength training for >/= 1 day/week
* Have no clinical evidence of cognitive failure as evidenced by Memorial Delirium Assessment Scale score of * Be aged 18 years or older
* Be willing to engage in follow-up telephone calls with a research staff
* Be willing to participate in the exercise programs
* Have telephone access so they can be contacted by the research staff
* Have a hemoglobin level of >/= 10 g/dL within 2 weeks of enrollment
* Be able to understand the description of the study and give written informed consent
* Have a Zubrod performance status score of 0 to 2
* Seen at an outpatient clinic at MD Anderson Cancer Center, its Houston Area Locations (HALs) or Smith Radiation Oncology Clinic (HHS)

Exclusion Criteria:

* Have a major contraindication to MethylphenidateMP) (e.g., allergy/hypersensitivity to study medications or their constituents), exercise (e.g., cardiac disease), or conditions making adherence difficult as determined by the attending physician
* Be currently taking MP, or have taken it within the previous 10 days
* Be unable to complete the baseline assessment forms (e.g., due to language or sensory barriers) or to understand the recommendations for participation in the study
* Need monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine
* Have glaucoma
* Have severe cardiac disease (New York Heart Association functional class III or IV)
* Have tachycardia and/or uncontrolled hypertension
* Be currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantone, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine).